Establishment of Fischer 344 rat model of ovarian cancer with lymphatic metastasis

2013 ◽  
Vol 289 (1) ◽  
pp. 149-154 ◽  
Author(s):  
Lingling Fan ◽  
Yingtao Liu ◽  
Xiaoyan Zhang ◽  
Yu Kang ◽  
Congjian Xu
2015 ◽  
Vol 25 (7) ◽  
pp. 1194-1200 ◽  
Author(s):  
Henri Azaïs ◽  
Gurvan Queniat ◽  
Caroline Bonner ◽  
Olivier Kerdraon ◽  
Meryem Tardivel ◽  
...  

ObjectiveOvarian cancer prognosis remains dire after primary therapy. Recurrence rates are disappointingly high as 60% of women with advanced epithelial ovarian cancer considered in remission will develop recurrent disease within 5 years. Special attention to undetected peritoneal metastasis and residual tumorous cells during surgery is necessary as they are the main predictive factors of recurrences. Folate receptor α (FRα) shows promising prospects in targeting ovarian cancerous cells. Our aim was to determine if the Fischer model described by Rose et al could be used to evaluate folate-targeted therapies in preclinical studies.MethodsNuTu-19 epithelial ovarian cancer cell line was used to induce peritoneal carcinomatosis in female Fischer 344 rats. FRα expression by NuTu-19 cells was assessed in vitro by immunofluorescence using “Cytospin®” protocol. In vitro folate-targeted compound uptake by NuTu-19 cells was evaluated by incubation of FRα-positive ovarian cancer cell lines (NuTu-19/SKOV-3/OVCAR-3/IGROV-1) with or without (control) a folate-targeted photosensitizer. Intracellular incorporation was assessed by confocal microscopy. Determination of in vivo FRα tissue expression by several organs of the peritoneal cavity was studied by immunohistochemistry.ResultsNuTu-19 cells express FRα which allows intracellular incorporation of folate-targeted compound by endocytosis. FRα is expressed in tumor tissue, ovary, and liver. Peritoneum, colon, small intestine, and kidney do not express the receptor.ConclusionsFemale Fischer 344 rat is an inexpensive reproducible and efficient preclinical model to study ovarian peritoneal carcinomatosis folate-targeted therapies.


2005 ◽  
Vol 15 (2) ◽  
pp. 246-254 ◽  
Author(s):  
K.D Sloan Stakleff ◽  
A.G Rouse ◽  
A.P Ryan ◽  
N.A Haller ◽  
V.E. Von Gruenigen

PLoS ONE ◽  
2012 ◽  
Vol 7 (10) ◽  
pp. e47639 ◽  
Author(s):  
Aimee L. Signarovitz ◽  
Heather J. Ray ◽  
Jieh-Juen Yu ◽  
M. N. Guentzel ◽  
James P. Chambers ◽  
...  

1986 ◽  
Vol 250 (6) ◽  
pp. R1047-R1051 ◽  
Author(s):  
J. Y. Wei ◽  
D. Mendelowitz ◽  
N. Anastasi ◽  
J. W. Rowe

To evaluate the influence of age per se on the carotid sinus baroreceptors in the absence of hypertension and atherosclerosis, we employed the Fischer 344 rat model. In 14 adult (A, 6-9 mo) and 9 senescent (S, 24-26 mo) normotensive male Fischer 344 rats the left carotid sinus region was vascularly isolated with sinus nerve intact and perfused with oxygenated modified Kreb's solution. Simultaneous measurements of intrasinus pressure and femoral arterial pressure response were obtained during linear pressure increases (20-200 mmHg) in the vascularly isolated sinus. There was no age difference in base-line arterial pressure or heart rate. Both age groups demonstrated similar positive relations between basal femoral arterial pressure and the magnitude of the femoral pressure response to equivalent carotid sinus pressures. There were similar estimated sinus volumes at onset of systemic response (39 +/- 1, A; 39 +/- 1 microliter, S), time to initial systemic pressure response (9 +/- 1, A; 7 +/- 1 s, S), mean rates of femoral pressure decline (1.8 +/- 0.3, A; 2.1 +/- 0.3 mmHg/s, S), and return to base line (1.5 +/- 0.3, A; 1.4 +/- 0.3 mmHg/s, S) as well as magnitudes of systolic (25 +/- 3, A; 26 +/- 4 mmHg, S) and diastolic (21 +/- 2 A; 22 +/- 4 mmHg, S) pressure drops. Thus, in the Fischer 344 rat model of aging, which differs from the human in that it is not complicated by hypertension or atherosclerosis, carotid sinus baroreflex function appears to be well maintained in senescence.


2018 ◽  
Vol 2018 ◽  
pp. 1-12 ◽  
Author(s):  
Laura E. Marshall ◽  
Michelle Nelson ◽  
Carwyn H. Davies ◽  
Adam O. Whelan ◽  
Dominic C. Jenner ◽  
...  

There is a requirement for an efficacious vaccine to protect people against infection fromFrancisella tularensis, the etiological agent of tularemia. The lipopolysaccharide (LPS) ofF. tularensisis suboptimally protective against a parenteral lethal challenge in mice. To develop a more efficacious subunit vaccine, we have used a novel biosynthetic technique of protein glycan coupling technology (PGCT) that exploits bacterial N-linked glycosylation to recombinantly conjugateF. tularensisO-antigen glycans to the immunogenic carrier proteinPseudomonas aeruginosaexoprotein A (ExoA). Previously, we demonstrated that an ExoA glycoconjugate with two glycosylation sequons was capable of providing significant protection to mice against a challenge with a low-virulence strain ofF. tularensis. Here, we have generated a more heavily glycosylated conjugate vaccine and evaluated its efficacy in a Fischer 344 rat model of tularemia. We demonstrate that this glycoconjugate vaccine protected rats against disease and the lethality of an inhalational challenge withF. tularensisSchu S4. Our data highlights the potential of this biosynthetic approach for the creation of next-generation tularemia subunit vaccines.


1994 ◽  
Vol 645 (1-2) ◽  
pp. 150-156 ◽  
Author(s):  
Alain M. Gardier ◽  
Sébastien Kachaner ◽  
Elisabeth Khan Shaghaghi ◽  
Christian Blot ◽  
Claude Bohuon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document